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Pancreatic cancerPancreatic intraepithelial neoplasia (PanIN) is the most common premalignant lesion of the pancreas.
Further understanding of the biological behavior and molecular genetic alterations in the stepwise pro-
gression of PanINs is necessary toward the development of pancreatic ductal adenocarcinoma (PDAC)
interventions. In this study, we analyzed the morphological characteristics, molecular alterations, and
biological behavior of pancreatic wild-type and neoplasia tissues, including analysis of PanIN cell line
SH-PAN (isolated from Pdx-1-Cre; LSL-KrasG12D/+ mouse) and PDAC cell line DT-PCa (isolated from
Pdx1-Cre; LSL-KrasG12D/+; LSL-Tp53R172H/+ mouse). Results show that KrasG12D induces ductal lesion PanINs.
Increased expression of EGFR, Her-2/Neu, p-MAPK and b-Catenin was observed in low-grade PanINs. Tp53
was not expressed in wild-type and low-grade PanINs, however, increased expression was observed in
high-grade PanINs. Furthermore, SH-PAN cells did not exhibit any colony formation and showed signif-
icantly lower migration and invasion ability compared with DT-PCa cells. Notably, we ﬁrst found PPP2R2A
(protein phosphatase 2, regulatory subunit B, alpha) expression was signiﬁcantly higher in SH-PAN cells
than DT-PCa cells, and was high in 96 of 172 peritumoral normal human pancreatic tissues and 20 of 36
human low- or middle-grade PanIN tissues, whereas, was weak or negligible in 12 of 20 human high-
grade PanIN tissues and 124 of 172 human PDAC tissues post-operation. The expression of PPP2R2A
appears to be correlated with clinical survival. Taken together, KrasG12D – driven PanIN showed the
tumorigenic ability, however, did not undergo a malignant transformation, and decreased expression
of PPP2R2A in PDACs may provided a new target for pancreatic carcinoma intervention.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Background
Pancreatic cancer is the fourth leading cause of cancer death in
the world. With an overall 5-year survival rate of less than 5%, pan-
creatic cancer has one of the poorest prognoses among all cancers
[1]. Therefore, it is of paramount importance to better understand
its precursor lesions and the pathological mechanisms regulatingthe genetic progression from normal cells to pancreatic ductal ade-
nocarcinomas (PDAC).
Pancreatic intraepithelial neoplasia (PanIN) is the most com-
mon pancreatic precursor lesion. Activating Kras mutations are al-
most uniformly present in the early stages of PanIN, whereas
subsequent inactivating mutations in p16, p53, and Smad4 occur
in advanced lesions [2–8]. However, because it is difﬁcult to isolate
and establish PanIN cell lines from the pancreatic tissue of pancre-
atic cancer patients, the previous studies of PanIN were mainly
conducted using a hybrid of PanIN and pancreatic cancer tissues.
The development of genetically engineered mouse models with
pancreatic cancer [9,10], speciﬁcally the progress in PanIN and
PDAC mouse models [11–13], has signiﬁcantly contributed to our
understanding of the genetics of pancreatic neoplasia [14,15].
Previous studies have isolated cell lines from the pancreas of
genetically engineered mutant mice with PanIN and PDAC
[11,12]. In this study, mouse pancreatic neoplasia tissues and
PanIN cell line isolated from the mutant mouse were employed
to study the biological features and molecular genetic alterations
of PanIN.
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2.1. Patient and tissue samples
PDAC and peritumoral normal tissue samples were obtained from 86 patients at
RuijinHospital inShanghai.Noneof thepatientshadpreviously receivedradiotherapy
or chemotherapy. After surgery, each tissue samplewas ﬁxed in formalin and embed-
ded in parafﬁn. Histological diagnoses were performed by two independent senior
pathologists in the Department of Pathology at Ruijin Hospital.
2.2. Mouse strains and cell lines
Genetically engineered mouse models were generated as previously described
[11,12]. Brieﬂy, LSL-KrasG12D mice, which are functionally heterozygous for the
wild-type allele (Kras+/), were crossed with Pdx-1-Cre mice to produce KrasG12D
(Pdx1-Cre;
LSL-KrasG12D/+) mice that develop ductal lesions identical to the stages of PanIN. The
classiﬁcation of PanIN stage was determined by the age of mice and tissue HE stain-
ing results. LSL-KrasG12D and LSL-Tp53R172H mice were crossed with Pdx-1-Cre trans-
genic mice to develop KrasG12D and Tp53R172H (Pdx1-Cre; LSL-KrasG12D/+; LSL-
Tp53R172H/+) mice that developed invasive and metastatic pancreatic ductal adeno-
carcinomas. The PanIN cell line (SH-PAN) was isolated from a Pdx1-Cre; LSL-
KrasG12D/+ mutant mouse, and PDAC cell lines (DT-PCa) were isolated from the
Pdx1-Cre;
LSL-KrasG12D/+; LSL-Tp53R172H/+ compound mutant mouse as previously reported
[11,12]. Early passage SH-PAN and DT-PCa cells were used in all experiments and
were grown in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM, Gibco) supplemented
with 10% fetal bovine serum (FBS), 100U/ml penicillin and streptomycin.
2.3. Cell proliferation, soft agar, invasion and migration assays
Detailed procedureswere followed as previously described [16]. Brieﬂy,MTTwas
used to assess cell proliferation, and a spectrophotometer measured the absorbance
at 490 nm.
For the soft agar assay, each well of six-well plate contained a bottom layer of
1.2% agarose, a middle layer of 0.64% agarose that included 5000 cells, and a top
layer of medium. The medium in the top layer was changed every six days. After
28 days, colonies were counted by using Quantity One analysis software (BioRad
Inc., Hercules, CA, USA) .
An invasion assay was performed with a Millicell invasion chamber (Millipore,
Billerica,MA, USA). The 8 lmpore insertswere coatedwith 15 lg ofMatrigel (Becton
Dickinson Labware, Bedford, MA, USA), and 1  105 cells were seeded in the top
chamber. The Matrigel invasion chamber was incubated for 20 h in a humidiﬁed tis-
sue culture incubator. Noninvasive cells were removed from the top of the Matrigel
with a cotton-tipped swab, and invading cells on the bottom surface of ﬁlter were
ﬁxed inmethanol and stainedwith crystal violet solution. Invasion ability was deter-
mined by counting the stained cells.
To assess cell migration, experimental procedures of a general cell invasion assay
were followed, with the exception that the porous polycarbonatemembranewas not
Matrigel. Cell migration ability was determined by counting the stained cells.
2.4. Mutation analysis of Kras, Tp53, p16 Ink4A, Smad4 and Cdk4
Themain geneticmutations related to the progression of pancreatic carcinoma in
SH-PANandDT-PCa cell lineswere analyzed. Total RNAwas extracted fromwild-type
murine pancreatic and SH-PAN cell lines using the RNeasy Mini Kit (Qiagen), and
cDNA was prepared using the First-Strand cDNA Synthesis Kit (Amersham Biosci-
ences) according tomanufacturers’ recommendations. PCRusingAmpli Taqpolymer-
ase (Applied Biosystems, Roche) mixed with PfuUltra HF DNA polymerase
(Stratagene, Cedar Creek, TX) was performed to amplify the K-ras, Tp53, p16Ink4A,
Smad4 and Cdk4 genes. Following electrophoresis, PCR products were excised from
1% agarose gel and puriﬁed using the QIAquick gel extraction kit (Qiagen Science,
Maryland, USA). Puriﬁed PCR fragments were digested with EcoRI/XhoI for DPC4/
Smad4, EcoRI/BamHI for K-ras, Tp53 and Cdk4 or PstI/BamHI for p16Ink4A, and were
subcloned into pBluescript II KS+ cloning vectors. After transformation into DH10B
cells by electroporation, the transformants were selected using LB plates with ampi-
cillin, X-gal and IPTG. A total of 8 white colonies for each cDNA were selected and
ampliﬁed. Plasmid DNA was puriﬁed using a QIAprep Spin Miniprep Kit (Qiagen Sci-
ence, Maryland, USA). Sequencing for each colony was performed at a DNA sequenc-
ing facility using standard universal T3 and T7 primers for K-ras, Tp53, p16Ink4A, Cdk4
and Smad4, additional primers for Smad4. To exclude the pseudomutations arising
from PCR, only mutation that were found in two ormore out of the eight clones were
recognized as validmutations. PCR conditions were as follows: denaturation at 95 C
for 30 s, annealing at 60 C for 1 min, and extension at 72 C for 1 min for a total of
30 cycles. The PCR primers used in this study are as follows:
Kras:
50-CGCGGAATTCGGCCTGCTGAAAATGACTGAG-30
50-GACAGGATCCTCACATAACTGTACACCTTGTCC-30
Tp53:50-GTCTGAATTCACTGGATGACTGCCATGGAGG-30
50-CGTTGGATCCAGGCAGTCAGTCTGAGTCAGG-30
p16INK4A:
50-CATACTGCAGATGGAGTCCGCTGCAGACAGACTGG-30
50-CTATGGATCCTTAGCTCTGCTCTTGGGATTGGC-30
Cdk4:
50-GGCTAGAATTCATGGCTGCCACTCGATATGAACC-30
50-GCTTGGATCCTCACTCTGCGTCGCTTTCCTCC-30
50-CAATCTCGAGCGCGGAGCCCAGGTCATCCTGC-30
50-GCGTGAATTCTCAGTCTAAAGGCTGTGGGTCCG-30
T3 and T7 primers for sequencing each plasmid DNA:
50-AATTAACCCTCACTAAAGGG-30
50-GTAATACGACTCACTATAGGGC-30
Primers for sequencing Smad4:
50-CGTTCACGACTTTGAAGGACAGC-30
50-CGTTTAAGGTCCCTTCAAGCTGC-30
50-CGATTACTTGGCGGGTGTTGG-30
50-GTGGACATTGGAGAGTTGACC-302.5. Subcutaneous nude mouse models
For subcutaneous nude mouse models, BALB/c nude mice were maintained un-
der speciﬁc pathogen-free conditions in the Shanghai Experimental Animals Center
of the Chinese Academy of Sciences, and cared for in accordance with institutional
guidelines. Mice were randomly assigned into 2 groups (5 mice/group) and 5  106
DT-PCa or SH-PAN cells were implanted subcutaneously in nude mice. Tumor vol-
ume (V) was estimated 4 weeks later post implantation using the formula
V = LW2p/6 (L: length of tumor; W: width of tumor).2.6. Histology and immunohistochemistry
Detailed procedures are provided as we have previously described [12].
Brieﬂy, tissues were ﬁxed in 10% formalin overnight and then embedded in par-
afﬁn. Serial 5-lm thick sections were cut from the tissue blocks, and dried over-
night in an oven at 60 C. The sections were dewaxed in xylene, dehydrated
using a series of alcohol gradations to water, and stained with HE for histological
veriﬁcation. Immunohistochemical analysis was performed on formalin-ﬁxed,
parafﬁn wax-embedded sections. All primary antibodies used were either rabbit
or goat polyclonal anti-mouse antibodies, and included antibodies for Tp53 (NCL-
p53-CM5P, NovoCastra, 1:500), phospho-p44/42-MAPK (Cell Signaling, 1:100),
Neu antibody (C-18,Snata Cruz, 1:200), EGFR (Cell Signaling, 1:50), Smad4 (B-8,
Santa Cruz, 1:50), b-Catenin (Santa Cruz, 1:200) and PPP2R2A (ab18136, Ab-
cam,1:1000). As a negative control, sections were incubated with PBS instead
of primary antibody. Signals were detected with biotinylated anti-rabbit/anti-
goat secondary antibodies (1:500, Vector) using the Elite Vectastain ABC kit
and peroxidase substrate DAB kit (Vector Laboratories, Burlingame, CA). Sections
were counterstained with Harris Hematoxylin. Immunohistochemical staining of
PPP2R2A in the cytoplasm and/or perinuclear region of PDAC and peritumoral
normal tissues was evaluated and semi-quantitatively estimated from the stain-
ing intensity and assigned grade 0 (no staining), grade 1 (weak staining), grade 2
(moderate staining) and grade 3 (strong staining). The percentage of positive
cells was scored from grades 0 to 3 as follows: grade 0, <1% of cancer cells
was negatively stained; grade 1, 1–49% positive expression; grade 2, 50–70% po-
sitive expression; and grade 3, >70% positive expression.2.7. Quantitative real-time PCR
To validate the expression of PPP2R2A (NM_002717.3), quantitative real-time
PCR was employed. The primer sequences used were F: 50-CAC-
TACGAGTGCCAGTCTTTAGG-30 , and R:
50-CTGCTGCTGTAATCAC CTCTGT-30 , and the product size was 246 bp. The assays
were completed using an ABI PRISM 7300 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA). Relative quantiﬁcation of lncRNA and mRNA
expression was determined using the comparative CT method. The expression
of lncRNAs and mRNAs in DT-PCa cells relative to SH-PAN cells was calculated
using the following formulas: DDCT = DCT DT-PCa  DCT SH-PAN, where fold
change = 2DDCT.
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Preparation of whole-cell lysates and electrophoresis were completed as pre-
viously described [16]. A sheep polyclonal anti-mouse PPP2R2A antibody
(1:1000, ab128031, Abcam, UK), a rabbit polyclonal anti-mouse AKT (1:1000,
ab6076, Abcam, UK) and a rabbit polyclonal anti-mouse AKT (phospho T308)
(1:1000, ab66134, Abcam, UK) were used as the primary antibodies, and HRP-
conjugated goat anti-rabbit or anti-sheep IgG (1:3000, Imgenex) were used as
secondary antibodies. Immunodetection was performed using an ECL Western
Blotting Detection Kit (Amersham Corp, UK). Relative protein expression levels
were quantiﬁed by densitometric measurement of the ECL reaction bands and
the results were normalized with values of GAPDH.
2.9. Statistical analysis
Statistical analyses were carried out using SPSS version 16.0. Each experiment
was repeated at least three times. The results are presented as the mean ± SD. Sig-
niﬁcant changes were assessed using Student’s t-tests for unpaired data. Post oper-
ation survival was evaluated by the Kaplan–Meier method and the log-rank test. P
values less than 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Oncogenic Kras mutation induces PanIN
It has been demonstrated that oncogenic KrasG12D induces the
formation of ductal lesions that recapitulate the full spectrum of
human PanIN in Pdx1-Cre; LSL-KrasG12D/+ mutant mice [11,12]. As
previously reported, the pancreas of Pdx1-Cre; LSL-KrasG12D/+ mu-
tant mice developed ductal lesions that were identical to all three
stages of human PanIN lesions, and both the total number and
grade of PanINs clearly increased with advancing age of the mice.
The characterization of PanINs is shown in Fig. 1. The wild-type
pancreas with normal cuboidal ductal epithelium (black arrow-
head), islet cells (is), and surrounding acinar tissue (ac) is pre-Fig. 1. Morphologic features of PanINs in genetically engineered mouse models. Upper
mutant mice (A–D, HE stain, original magniﬁcation 200). (A) Wild-type pancreas: norm
PanIN-1 stage: columnar or cuboidal cells. (C) PanIN-2 stage: loss of polarity and moder
nuclear atypia, and budding of cell clusters into the ductal lumen. PanIN (black arrow). Lo
cell line, named SH-PAN, isolated from Pdx1-Cre; LSL-KrasG12D/+ mutant mice (F), and p
KrasG12D/+; LSL-Tp53R172H/+ compound mutant mice (G).sented (Fig. 1A). Low-grade PanIN lesions (PanIN-1) were
composed of ﬂat or papillary columnar or cuboidal cells (black ar-
row) that retained their nuclear polarity and lacked nuclear atypia
(Fig. 1B). Intermediate-grade PanIN lesions (PanIN-2), which are
slightly more architecturally complex than PanIN-1 lesions, pre-
sented nuclear abnormalities such as a loss of polarity, crowding,
variable size (pleomorphism), hyperchromasia, and pseudo-strati-
ﬁcation, however the presence of mitoses were rare (black arrow)
(Fig. 1C). High-grade PanIN lesions (PanIN-3) displayed a wide-
spread loss of polarity, marked nuclear atypia, and prevalent mito-
ses within the basement membrane (black arrow) (Fig. 1D). These
results demonstrate that activating Krasmutations induce the pro-
gression of PanIN.
Based on previous studies [11,12] that determined pancreatic
ductal lesions were principally low-grade (Fig. 1A and B) at 4–
5 months with no occurrence of PDAC, a primary normal pancre-
atic cell line, named NPC, was isolated from the pancreas of a 4-
month-old wild-type genetically engineered mouse (Fig. 1E), and
a low-grade PanIN cell line, named SH-PAN, was isolated from
the pancreas of a 4-month-old genetically engineered Pdx-1-Cre;
LSL-KrasG12D/+ mutant mouse (Fig. 1F). Pdx-1-Cre; LSL-KrasG12D/+;
LSL-Tp53R172H/+ compound mutant mice were established from
which the pancreatic ductal adenocarcinoma cell line, named DT-
PCa, was isolated (Fig. 1G). In this study, the eighth passage (P8)
of SH-PAN cells was used in experiments and DT-PCa and NPC cells
were used as controls.
3.2. Differential expression of EGFR, Her-2/Neu, p-MAPK, b-Catenin,
Tp53 and Smad4 in the progression of pancreatic neoplasias
EGFR, Her-2/Neu, p-MAPK and b-Catenin have been suggested to
be involved in the malignant transformation of cells through differ-panel: microscopic histological features of the pancreas of Pdx1-Cre; LSL-KrasG12D/+
al ﬂat ductal epithelium (black arrowhead), islet cells (is), and acinar tissue (ac). (B)
ate nuclear atypia. (D) PanIN-3 stage: complete loss of cellular polarity, signiﬁcant
wer panel: in vitro cultured wild-type pancreatic ductal cell line (E), low-grade PanIN
ancreatic ductal carcinoma cell line, named DT-PCa, isolated from Pdx-1-Cre; LSL-
138 R. Shen et al. / Cancer Letters 339 (2013) 135–143ent pathways. Therefore, we compared the expression of p-MAPK,
EGFR, Her-2/Neu, and b-Catenin between wild-type pancreatic tis-
sues and PanIN tissues. P-MAPK, EGFR, Her-2/Neu, and b-Catenin
were not expressed in the ductal tissues (red arrow), acinar cells
(ac) or islet cells (is) of the wild-type pancreas (Fig. 2A, D, G, and
J), however, they were strongly expressed in the cell membranes
and cytoplasm of all stages of PanIN cells (Fig. 2B, C, E, F, H, I, K
and L). P-MAPK was highly expressed in the nucleus of PanIN cells
(Fig. 2B and C).
Due to Tp53 and Smad4 genes were inactivated in a large pro-
portion of human late stage PanINs, both were also detected in dif-
ferent stages of murine PanINs and PDAC. As shown in Fig. 3,
different immunohistochemical characteristics of Tp53 and Smad4
in both wild-type pancreatic tissues and PanIN tissues (Fig. 3) were
observed. Smad4 staining was weak in ductal cells (arrowhead),
strong in acinar cells (ac), and especially intense in islet cells
(Fig. 3A–C). However, there was no signiﬁcant difference in the
expression of Smad4 in ductal cells among wild-type pancreatic
tissues (Fig. 3A), early grade PanIN tissues (Fig. 3B) and late grade
PanIN tissues (Fig. 3C). Ductal cells (black arrowhead), islet cells
(is), acinar cells (ac) of the wild-type pancreas (Fig. 3D), and low-Fig. 2. Expression of oncogenic proteins in the pancreas of Pdx1-Cre; LSL-KrasG12D/+ muta
F), Her-2/Neu (G–I), and b-Catenin (J–L) are shown for pancreases from wild-type mice (
400). Normal pancreatic ducts (red arrow), islet cells (is), acinar cells (ac), and PanIN tiss
Catenin was observed in low- and intermediate-grade PanIN cells. (For interpretation of t
of this article.)grade PanIN tissues of both Pdx-1-Cre; LSL-KrasG12D/+ mutant
mouse (Fig. 3E, red arrow) and Pdx-1-Cre; LSL-KrasG12D/+; LSL-
Tp53R172H/+ compound mutant mice (Fig. 3G, red arrow) lacked
Tp53 expression. However, punctate expression of Tp53 was ob-
served in the nucleus of high-grade PanIN cells in Pdx-1-Cre; LSL-
KrasG12D/+ mutant mouse (Fig. 3F, red arrow) and was highly ex-
pressed in the nucleus of pancreatic cancer cells in Pdx-1-Cre;
LSL-KrasG12D/+; LSL-Tp53R172H/+ compound mutant mice (Fig. 3G
and H, black arrow).
The results above suggest that high expression of EGFR, Her-2/
Neu, p-MAPK and b-Catenin in low-grade PanIN tissues occurs in
the early stages of PanIN, whereas increased Tp53 expression ap-
pears in the late stages of PanIN, and Smad4 expression remains
constant among the stages of PanIN.
3.3. Kras gene mutation is an early genetic abnormality of pancreatic
neoplasia
Kras, p16, Tp53 and Smad4 genes are recognized as the most
common dysfunctional genes associated with pancreatic carcino-
genesis. Therefore, multiple mutation analyses of Kras, p16, Tp53,nt mice. Representative immunohistochemical staining for p-MAPK (A–C), EGFR (D–
A, D, G, J, 50) and Pdx1-Cre; LSL-KrasG12D/+ mutant mice (B, E, H, K, 100; C, F, I, L,
ues (black arrow) are indicated. Strong staining of p-MAPK, EGFR, Her-2/Neu, and b-
he references to color in this ﬁgure legend, the reader is referred to the web version
Fig. 3. Expression of tumor suppressor proteins in the pancreas. Representative immunohistochemical staining of Smad4 (A–C, 400) and Tp53 (D and H, 400) in a wild-
type pancreas (A and D), a low-grade PanIN (B, E, and G), a high-grade PanIN (C and F) and cancerous pancreatic ductal tissue (G and H) are shown. Normal pancreatic ducts
(black arrowhead), acinar cells (ac), islet cells (is), PanIN tissues (red arrow) and pancreatic carcinomas (black arrow) are indicated. Pancreases were isolated from Pdx1-Cre;
LSL-KrasG12D/+ mice (B, C, E, and F) and Pdx-1-Cre; LSL-KrasG12D/+; LSL-Tp53R172H/+ mice (G and H). Smad4 staining was weak in ductal cells (arrowhead) but strong in islet (is)
and acinar cells (ac). Tp53 staining was absent in wild-type pancreas (D) and low-grade PanIN tissues (E, G, red arrow). However, punctate Tp53 staining was observed in the
nucleus of high-grade PanIN cells (3F, red arrow), and intense Tp53 staining was found in the nucleus of pancreatic cancer cells (G and H, black arrow). (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1
Sequence analysis of Kras, Tp53, p16, Smad4 and Cdk4.
Cell Kras Tp53 p16 Smad4 Cdk4
Wt N N N N N
SH-PAN G12D N N N N
DT-PCa G12D R172H N N N
Note: N, no mutation or deletion.
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Results are shown in Table 1. Except for the mutation of KrasG12D,
no mutation or deletion of p16, Tp53, Smad4 and Cdk4 in SH-PAN
cells was observed. Furthermore, no mutation or deletion of p16,
Smad4 and Cdk4 in DT-PCa cells was found except for the mutation
of KrasG12D and Tp53R172H. These results clearly suggest that the
activated mutation of KrasG12D could be one of the earliest genetic
abnormalities of pancreatic neoplasia and is sufﬁcient to initiate
the transformation of pancreatic ductal cells to PanINs and that
Tp53R172H and KrasG12D cooperate to develop metastatic pancreatic
ductal adenocarcinomas.3.4. Aberrant biological behavior of PanINs
Although some knowledge about PanIN are well known, direct
and dynamic observation to biological behaviors of PanIN is few,
so our study is to directly compare the features of cell lines
between PanIN and PDAC. Cell proliferation was determined using
an MTT assay, and rapid growth was observed in both the SH-PAN
and DT-PCa cells. The DT-PCa cells grew faster than the SH-PAN
cells, and by the third day, signiﬁcantly different growth was
observed between DT-PCa and SH-PAN cells (p < 0.05) (Fig. 4A).
To determine the effect of PanIN cells on tumorigenesis in vitro,
a soft agar colony formation assay was performed, and wild-type
pancreatic and DT-PCa cells were used as a control. After 16 days
of culture on soft agar, the DT-PCa cells showed rapid anchorage-
independent growth and formed large colonies. After 28 days of
culture, the DT-PCa cells had formed 286 colonies, whereas no col-ony formation was observed for either the wild-type pancreatic
ductal cells or the SH-PAN cells (Fig. 4B). SH-PAN cells did not
demonstrate anchorage-independent growth or colony formation,
which indicates that PanINs lack the ability to undergo malignant
transformations in vitro.
Moreover, a Matrigel transwell assay was performed to assess
the migration of DT-PCa and SH-PAN cells. Representative staining
results and bar chart are shown in Fig. 4C. Results indicate signiﬁ-
cantly lower migration ability of SH-PAN cells compared with the
control DT-PCa cells (p < 0.05). A Matrigel invasion assay was also
performed to assess the invasion of SH-PAN and DT-PCa cells. Rep-
resentative staining results and bar charts are shown in Fig. 4D.
The Matrigel transwell invasion assay showed signiﬁcantly lower
invasion ability of SH-PAN cells compared with the control DT-
PCa cells (p < 0.05).
The tumorigenic potential of SH-PAN and DT-PCa cells in vivo
was assessed by tumor formation in BALB/c nude mice, and the
volume of the transplanted tumor was compared between SH-
PAN and DT-PCa cells. The data, which is summarized in Fig. 5A,
shows that rapid tumor growth was observed in both SH-PAN
and DT-PCa cells and that the DT-PCa cells grew signiﬁcantly faster
than SH-PAN cells (p < 0.05). Histological analyses of xenograft tu-
mors formed by SH-PAN cells revealed low-grade PanIN lesions
that were characterized by an absence of nuclear atypia and few
mitoses (Fig. 5B, left). However, xenograft tumors formed by DT-
PCa cells demonstrated a widespread loss of polarity, nuclear aty-
pia (arrowhead), and numerous mitoses (arrow) (Fig. 5B, right).
Furthermore, immunohistochemical results revealed that prolifer-
ating cell nuclear antigen (PCNA) was more highly expressed in the
nucleus of xenograft tumors formed by DT-PCa cells than in tumors
formed by SH-PAN cells (Fig. 5C).
These results suggest that the activated mutation of Kras might
promote cell transformation and proliferation.
3.5. Decreased PPP2R2A expression in human PDAC
Based on our previous study in gene expression proﬁling in
which a signiﬁcantly differential expression of PPP2R2A was iden-
140 R. Shen et al. / Cancer Letters 339 (2013) 135–143tiﬁed between SH-PAN and DT-PCa cells (data not show), the
PPP2R2A gene was selected for further study because of its un-
known expression and clinical signiﬁcance in human pancreatic
cancer. Real-time PCR and Western blot analysis showed that
PPP2R2A expression was signiﬁcantly downregulated in DT-PCa
cells compared with SH-PAN cells (Fig. 6A). Moreover, we found
signiﬁcantly increased phosphorylation of AKT in DT-PCa cells
compared with SH-PAN cells, suggesting that PPP2R2A expression
may be inversely related to AKT phosphorylation (Fig. 6A). Immu-
nohistochemistry was performed and the results are summarized
in a bar chart that presents the percentage of cells with grades 0,
1, 2 or 3 staining (Fig. 6B and C). PPP2R2A expression with intense
staining (grades 2 and 3) in the cytoplasm and nucleus was de-
tected in 96 of 172 human peritumoral normal pancreatic tissues
and 20 of 36 low-grade and middle-grade PanIN tissues (PanIN-I
or PanIN-II) post-operation, respectively. In contrast, weak or neg-
ligible PPP2R2A expression (grades 1 and 0) was observed in the
cytoplasm and nucleus in 12 of 20 high-grade PanIN tissues (Pa-
nIN-III) and in 124 of 172 human PDAC tissues. Furthermore, Kap-
lan–Meier analysis showed that the median survival of PPP2R2A-
strong positive (grades 2 and 3) and PPP2R2A-weak positive/nega-Fig. 4. Biological behavior of PanIN cells. (A) Cell proliferation of PanIN cells (SH-PAN) a
pancreatic ductal cells (wt). Rapid growth was observed in both SH-PAN and DT-PCa cells
from the activated mutation of KrasG12D. (B) The anchorage-independent growth of SH-P
cells line at day 16 and day 28 (photomicrograph, 50), and the number of colonies is s
PAN and wild-type cells did not have anchorage-independent growth or colony formatio
were performed to assess the migration and invasion activity of the tumor cells. Represen
PCa cells, right). The results are summarized in the bar chart, which presents the numbe
than SH-PAN cells (p < 0.05). These experiments were performed in triplicate and eachtive (weak staining, grade 1; negligible staining, grade 0) patients
was 19.46 and 11.37 months, respectively (p = 0.009) (Fig. 6D). This
ﬁnding demonstrates that PPP2R2A expression appears to be corre-
lated with clinical survival.4. Discussion
Pancreatic ductal adenocarcinoma is believed to follow an ade-
noma to carcinoma progression model similar to that which is as-
cribed to colorectal adenocarcinoma [17,18]. PanINs are the most
common precursor lesions of the pancreas [19,20]. It is well known
that Kras mutations are the most common genetic alterations and
that they occur in nearly all pancreatic cancers. Oncogenic Kras
mutations impair intrinsic guanosine triphosphatase activity,
which initiates cell proliferation and immortalization by persistent
activation of Raf/MEK/ERK1/2 [21,22]. Our previous studies showed
that endogenous expression of KrasG12D in MEFs stimulated prolif-
eration and partial transformation and that the initiation of trans-
formation may not require additional genetic events [23]. To
exploit the role of mutant Kras in the initiation of pancreatic neo-nd pancreatic ductal adenocarcinoma cells (DT-PCa) was compared with wild-type
, however the DT-PCa cells grew faster than the SH-PAN cells. SH-PAN cells resulted
AN cell line was compared with both DT-PCa cells and wild-type pancreatic ductal
hown. DT-PCa cells showed rapid anchorage-independent growth, whereas the SH-
n after 28 days in culture. Transwell chamber migration (C) and invasion (D) assays
tative pictures are shown (C and D: photomicrograph, 200; SH-PAN cells, left; DT-
r of cells. DT-PCa cells showed signiﬁcantly higher migration and invasion abilities
number is an average value.
Fig. 5. Tumorigenic potential of PanIN cells. (A) Tumor volumes of xenografts formed by either SH-PAN or DT-PCa cells were compared. Rapid tumor growth was observed
with both SH-PAN and DT-PCa cells, however the DT-PCa cells grew signiﬁcantly faster than SH-PAN cells (p < 0.05). (B) Histological analysis of the xenograft tumors formed
by SH-PAN and DT-PCa cells revealed that the former (B, left) presented low-grade PanIN lesions with no nuclear atypia and few mitoses, whereas the latter (B, right)
presented widespread loss of polarity, prevalent nuclear atypia (arrowhead), and numerous mitoses (arrow) (400). (C) Immunohistochemical staining of parafﬁn-embedded
xenograft tumors tissues showed increased expression of PCNA (nucleus) in the tumors formed by DT-PCa cells, compared with the tumors formed by SH-PAN cells (400).
R. Shen et al. / Cancer Letters 339 (2013) 135–143 141plasias, endogenous expression of KrasG12D was directed to progen-
itor cells in the pancreas of mice by crossing LSL-KrasG12Dmice with
Pdx1-Cre mice that express Cre-recombinase from a pancreatic-
speciﬁc promoter [11,12].
PanINs show evidence of histological progression [11]. Both the
total number of and grade of PanINs clearly increased with advanc-
ing age of the mice. Although expression of mutant Kras itself is not
sufﬁcient to develop an invasive cancer, it is sufﬁcient to initiate
PanIN. In LSL-KrasG12D/Pdx1-Cre mice with an average age of
4.5 months, the majority of duct lesions in the pancreas were
low-grade PanINs (PanIN IA and 1B), with few high-grade PanINs
and no carcinomas observed. Based on this detailed observation,
a PanIN cell line, SH-PAN, was isolated from the pancreas of a 4-
month-old Pdx-1-Cre; LSL-KrasG12D/+ mutant mouse, and a PDAC
cell line, DT-PCa, isolated from the pancreas of Pdx-1-Cre; LSL-
KrasG12D/+; LSL-Tp53R172H/+ compound mutant mouse was used as
a control.
Although PanIN has been well studied, there have been few di-
rect and dynamic observations using PanIN tissues and cell lines.
Therefore, our study directly compared the characteristics of PanIN
and PDAC tissues and cell lines to identify new biological behaviors
of PanIN. Here, our study conﬁrms that PanIN cells contain genetic
KrasG12D mutations but no genetic mutations or deletions in p16,
Tp53, or Smad4. Additionally, we demonstrated that high expres-
sion of EGFR, Her-2/Neu, p-MAPK and b-Catenin in low-grade PanIN
tissues is associated to events in the early stages of PanIN, whereasincreased expression of Tp53 that occurs during late stage PanIN is
associated with pancreatic neoplasia progression. These results
demonstrate the early molecular events in the progression of
PDAC. Then, we investigated the biological features of PanIN.
Although PanINs possess tumorigenic ability in vivo, a malignant
transformation was not observed. The dysfunction of the tumor
suppressor gene Tp53 promotes the progression of PanIN to carci-
noma, which proves those known importance in the progression of
PDAC. Therefore, our studies clearly suggest that the tumor sup-
pressor genes Tp53, Smad4, and p16 are abnormally expressed in
human pancreatic carcinomas but do not play a key role in the
transformation of early-stage PanIN cells.
PCNA is well known to be related to DNA replication and cell
proliferation in mammalian cells. PCNA is widely used as a marker
of cell proliferation in various tumors, including pancreatic cancer
[24]. Therefore, the difference of PCNA expression between PanIN
SH-PAN cells and PDAC DT-PCa cells may be related to dysfunc-
tional Tp53.
The PP2A holoenzyme consists of a structural subunit, a cata-
lytic subunit, and a variable regulatory subunit. PPP2R2A encodes
an alpha isoform from the regulatory subunit B55 subfamily
(B55a). Kuo et al. [25] demonstrated that B55a-dependent target-
ing of the PP2A holoenzyme to Akt selectively controlled Akt phos-
phorylation at Thr-308 to regulate cell proliferation and survival.
PPP2R2A has not been previously implicated in pancreatic ductal
neoplasia. Intriguingly, we discovered that Tp53R172H expression
Fig. 6. Expression of PPP2R2A in pancreatic lesions. (A) Gene expression was quantiﬁed in SH-PAN and DT-PCa cells by real-time PCR and Western blot. (B and C)
Immunohistochemical assessment of PPP2R2A levels in human pancreatic lesions was performed (100 magniﬁcation, 400 magniﬁcation of the boxes indicated). The
results are summarized in the bar chart, which presents the percentage of cells with grades 0, 1, 2 and 3 staining. Intense expression of PPP2R2A was observed in peritumoral
normal tissues, low-grade and middle-grade PanIN tissues, whereas weak or negligible expression was observed in high-grade PanIN tissues and PDAC tissues. (D) Kaplan–
Meier survival curve of PPP2R2A – strong positive (strong staining, grades 2 or 3) and PPP2R2A-weak positive/negative (weak or negligible staining, grades 1 or 0).
142 R. Shen et al. / Cancer Letters 339 (2013) 135–143was relative to the reduced expression of PPP2R2A and that
PPP2R2A expression appears to be correlated with clinical survival.
Moreover, we also found that PPP2R2A expression may be nega-
tively related to the activation of AKT. Although we did not provide
sufﬁcient evidence to deﬁne PPP2R2A as a tumor suppressor in
pancreatic carcinogenesis, the present data may provide us with
novel and potential molecular target in carcinogenesis that re-
quires further investigation.
Taken together, this study on gene targeting mouse models pro-
vides further insight on the biological characteristics of PanIN. Our
data suggest the reduced expression of PPP2R2A in PDAC may pro-
vide a novel and potential target toward the development of dis-
ease interventions for pancreatic carcinomas.Author contributions
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